Well-known companies including Pfizer, Allergan and GlaxoSmithKline put up the price of their medicines on January 1 in a move that will lead to higher bills for patients. Now some investors are asking whether politicians might pursue regulations to curb the practice.<br /><br />► Subscribe to FT.com here: http://bit.ly/2r8RJzM<br /><br />► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs<br /><br />For more video content from the Financial Times, visit http://www.FT.com/video<br /><br /><br />Twitter https://twitter.com/ftvideo<br />Facebook https://www.facebook.com/financialtimes
